Viromed Medical

Regulatory Filings • Nov 26, 2025

News Details

Ad-hoc | 26 November 2025 17:02

Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care

Viromed Medical AG / Key word(s): Alliance/Miscellaneous

Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care

26-Nov-2025 / 17:02 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group .

The issuer is solely responsible for the content of this announcement.

---

AD HOC ANNOUNCEMENT

Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care

Pinneberg, November 26, 2025 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), confirms market rumors that the company is in advanced talks with a global MedTech company in the field of wound treatment about signing a cooperation agreement. This mainly involves the use of the cold plasma medical device ViroCAP®/OEM to support wound healing.

Viromed will inform shareholders of further developments in an appropriate manner and in accordance with the legal obligations.

Notifying person:

Uwe Perbandt, CEO Viromed Medical AG

Contact Viromed:

E-Mail: kontakt@viromed-medical.de

End of Inside Information

---

26-Nov-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

View original content: EQS News

---

Language:	English
Company:	Viromed Medical AG
	Hauptstraße 105
	25462 Rellingen
	Germany
E-mail:	kontakt@viromed-medical.de
Internet:	https://www.viromed-medical-ag.de/
ISIN:	DE000A3MQR65
WKN:	A3MQR6
Listed:	Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange
EQS News ID:	2236382

End of Announcement	EQS News Service

---

2236382  26-Nov-2025 CET/CEST